Lacrosse NSE ALPHA Coronary Dilatation Catheter
NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) · Decision date Jul 22, 2026
What did the FDA decide?
FDA records P230026/S003 as a supplement to PMA P230026, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 22, 2026.
FDA approval order statement
a cleanroom renovation (new equipment) and the relocation of a dust collector machine
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 22, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P230026/S003
- Regulatory pathway
- PMA supplement
- Product code
- NWX
- Decision code
- OK30
- Decision date
- Jul 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring.
- Product code
- NWX
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230026/S003 received
Application receipt date recorded by FDA.
P230026/S004 · Related supplement
Lacrosse NSE ALPHA Coronary Dilatation Catheter
P230026/S005 · Related supplement
Lacrosse NSE ALPHA Coronary Dilatation Catheter
P230026/S003 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S004 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Lacrosse NSE ALPHA Coronary Dilatation CatheterP230026/S005 | NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.) | PMA supplement | Jul 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NWX
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Scoreflex NC Scoring PTCA CatheterP200041/S005 | OrbusNeich Medical (Shenzhen) Co., Ltd. | PMA supplement | Jul 31, 2026 | FDA |
WOLVERINE Coronary Cutting BalloonP950020/S148 | Boston Scientific Corp | PMA supplement | Jan 27, 2026 | FDA |
WOLVERINE Coronary Cutting BalloonP950020/S147 | Boston Scientific Corp | PMA supplement | Dec 1, 2025 | FDA |
Scoreflex NC Scoring PTCA CatheterP200041/S009 | OrbusNeich Medical (Shenzhen) Co., Ltd. | PMA supplement | Oct 29, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
NIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5f Kdx Nagoya Sakae Bldg., 4-5-3, Sakae, Naka-Ku, Nagoya
Sources and methodology
- Original FDA record: P230026/S003
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

